The Digital Breast Tomosynthesis (DBT) Market was valued at USD 3.88 billion in 2024. The Digital Breast Tomosynthesis (DBT) Market industry is projected to grow from USD 4.37 billion in 2025 to USD 13.18 billion by 2035, exhibiting a compound annual growth rate (CAGR) of 11.68% during the forecast period (2025-2035).
The increasing prevalence of breast cancer and technological advancements and shift toward early and preventive diagnosis are driving the growth of the Digital Breast Tomosynthesis (DBT) Market.
As per the Analyst at MRFR, the rising global prevalence of breast cancer is a key driver behind the rapid growth of the digital breast tomosynthesis (DBT) market. According to the WHO, in 2022 alone, 2.3 million women were diagnosed with breast cancer, and 670,000 died from the disease, underscoring the critical need for early and accurate detection. In the U.S., the National Breast Cancer Foundation, Inc. reports that 1 in 8 women will be diagnosed with breast cancer in their lifetime, with 316,950 women and 2,800 men expected to be diagnosed with invasive breast cancer in 2025, along with 59,080 new cases of non-invasive (in situ) breast cancer.
These alarming statistics have intensified demand for advanced screening technologies like 3D mammography (tomosynthesis), which offers higher detection rates and fewer false positives compared to traditional 2D mammography. Governments and healthcare providers are increasingly adopting DBT in screening programs, while technological advancements and growing awareness further propel market expansion.
FIGURE 1: DIGITAL BREAST TOMOSYNTHESIS (DBT) MARKET VALUE (2019-2035) USD BILLION
Source: Secondary Research, Primary Research, MRFR Database, and Analyst Review
Expansion into emerging markets is creating significant and lucrative growth opportunities for the global tomosynthesis market. Developing regions such as Asia-Pacific, Latin America, and parts of the Middle East and Africa are experiencing a surge in breast cancer incidence, coupled with growing awareness of the importance of early detection and diagnosis. Governments in these regions are increasingly investing in healthcare infrastructure, initiating national screening programs, and encouraging the adoption of advanced imaging technologies like digital breast tomosynthesis (DBT). As per India’s Union Budget 2025, the government’s strong push for private sector participation supported by regulatory reforms and a USD 1,756.83 infrastructure boost—is set to unlock new avenues for innovation and investment.
The proposed AI Development Center, along with regional skilling hubs developed through global collaborations, aims to modernise healthcare delivery and diagnostics across the country. Additionally, the rising middle-class population and improving healthcare access are boosting demand for high-quality diagnostic services. Medical device manufacturers are recognizing the untapped potential in these markets and are strategically expanding through partnerships, localized manufacturing, and cost-effective solutions tailored to regional needs. As a result, emerging markets are becoming key growth drivers, offering new revenue streams and accelerating the global adoption of tomosynthesis systems.
Based on Product, this segment includes 2D/3D Combo and 3D-Only. The 2D/3D Combo segment dominated the global market in 2024, while the 3D-Only segment is projected to be the fastest–growing segment during the forecast period. The 2D/3D combination mammogram is an advanced method for breast cancer screening that uses both traditional 2D mammography and 3D tomosynthesis. The 2D mammogram captures a standard image of the breast from two angles, while the 3D tomosynthesis takes multiple images from different angles and puts them together to create a detailed 3D picture.
This combination helps doctors find problems more accurately, especially in women with dense breast tissue where 2D images might miss some issues. The 2D/3D combo also reduces the chances of false positives, meaning fewer women will need unnecessary follow-up tests. While there’s a slight increase in radiation exposure compared to a regular 2D mammogram, the extra clarity and accuracy make it a valuable tool for early breast cancer detection.
FIGURE 2: DIGITAL BREAST TOMOSYNTHESIS (DBT) MARKET SHARE BY PRODUCT 2024 AND 2035 (USD BILLION)
Source: Secondary Research, Primary Research, MRFR Database and Analyst Review
Based on Configuration, this segment includes U-Arm and Others. The Others segment dominated the global market in 2024, while the U-Arm segment is projected to be the fastest–growing segment during the forecast period. C-arm tomosynthesis devices are emerging as a valuable innovation in the breast cancer diagnostics, offering high-resolution 3D imaging that significantly enhances the accuracy of tumor detection and characterization.
Unlike conventional 2D mammography, tomosynthesis captures multiple images from different angles, allowing radiologists to examine breast tissue in thin slices and identify malignancies that may be obscured in dense tissue. These systems are particularly beneficial in biopsy guidance and intraoperative imaging, enabling precise localization and assessment of lesions. As healthcare providers seek to improve early detection rates and reduce recall rates, the demand for C-arm tomosynthesis solutions tailored to breast cancer applications is growing steadily, supported by advancements in imaging technology and increased focus on patient-centered care.
Based on Application, this segment includes Breast Cancer Screening and Diagnostic Imaging. The Breast Cancer Screening segment dominated the global market in 2024, while the Diagnostic Imaging segment is projected to be the fastest–growing segment during the forecast period. The use of tomosynthesis in breast cancer screening is revolutionizing community health methods by boosting early detection rates, particularly in women with thick breast tissue.
As a screening modality, 3D tomosynthesis greatly reduces recall rates and false positives, hence improving clinical workflow and lowering downstream costs associated with unnecessary follow-up imaging. Healthcare providers who use tomosynthesis for routine screening gain a competitive advantage by providing patients with more accurate and comfortable scans, generally with equivalent or lower radiation exposure than when synthetic 2D pictures are used. Strategically, investing in DBT promotes quality-based care initiatives, improves compliance with breast screening standards, and reinforces a facility's reputation for providing advanced, patient-centered diagnostics.
Based on End-User, this segment includes Hospitals and Specialty Clinics, Diagnostic Imaging Centers, Research & Academic Institute. The Hospitals and Specialty Clinics segment dominated the global market in 2024, while the Diagnostic Imaging Centers segment is projected to be the fastest–growing segment during the forecast period. Hospitals and specialty clinics are representing important end-user sectors in the tomosynthesis industry, with each playing a crucial role in its continued expansion.
Hospitals dominate the market because of their extensive diagnostic infrastructure, ability to handle large patient volumes, and integration of modern imaging technologies into multidisciplinary treatment pathways. Their investment in DBT is consistent with larger institutional aims such as improving diagnostic accuracy, patient outcomes, and satisfying value-based care criteria. In parallel, specialized clinics, particularly imaging and women's health centers, emerging as significant providers, utilizing DBT to provide accessible, early detection services in outpatient settings. Their focused service delivery strategy and smaller operating costs allow for rapid adoption of new technologies, positioning them as significant drivers of market expansion and innovation.
Based on the Region, the global Digital Breast Tomosynthesis (DBT) are segmented into North America, Europe, Asia-Pacific, South America and Middle East & Africa. The North America dominated the global market in 2024, while the Asia-Pacific is projected to be the fastest–growing segment during the forecast period. Major demand factors driving the North America market are the increasing prevalence of breast cancer and technological advancements and shift toward early and preventive diagnosis.
The North American tomosynthesis market is expanding rapidly, driven by a number of major factors such as rising breast cancer rates, technological improvements, and increased need for more precise diagnostic techniques. For example, the prevalence of breast cancer in North America is rising. According to the American Cancer Society, approximately one out of every eight women in the United States may acquire breast cancer over their lifetime.
This has resulted in increased adoption of advanced screening methods, such as tomosynthesis, which improves early detection rates. The increased awareness of breast cancer, combined with updated screening standards, is encouraging healthcare professionals to use digital breast tomosynthesis (DBT) as a tool to improve early diagnosis and eliminate false positives often associated with traditional mammography.
FIGURE 3: DIGITAL BREAST TOMOSYNTHESIS (DBT) MARKET VALUE BY REGION 2024 AND 2035 (USD BILLION)
Source: Secondary Research, Primary Research, MRFR Database, and Analyst Review
Further, the countries considered in the scope of the Application Tracking System Market are the US, Canada, Germany, France, UK, Italy, Spain, Russia, China, India, Japan, South Korea, Malaysia, Thailand, Indonesia, Brazil, Mexico, Argentina, GCC Countries, South Africa and others.
Many global, regional, and local vendors characterize the Digital Breast Tomosynthesis (DBT) Market. The market is highly competitive, with all the players competing to gain market share. Intense competition, rapid advances in technology, frequent changes in government policies, and environmental regulations are key factors that confront market growth. The vendors compete based on cost, product quality, reliability, and government regulations. Vendors must provide cost-efficient, high-quality products to survive and succeed in an intensely competitive market.
The major competitors in the market are Hologic, Inc., GE HealthCare, FUJIFILM Holdings Corporation, Trivitron Healthcare Private Limited, Planmed Oy, Siemens Healthineers, PerkinElmer, Canon Medical Systems Corporation, Analogic Corporation, Shimadzu Corporation, NP JSC AMICO, VMI Médica, BEMEMS Co., Ltd., Sino Medical-Device Technology Co., Ltd., Shenzhen Landwind Industry Co., Payamed Electronic Industries Co., Medical Technologies Ltd. (MTL), Metaltronica S.p.A., Lotus Healthcare, Koninklijke Philips N.V., Allengers Medical Systems Ltd., IMS Giotto S.p.A., Shenzhen Angell Technology Co., Ltd., Konica Minolta, Inc., Electron Co. are among others. The Digital Breast Tomosynthesis (DBT) Market is a consolidated market due to increasing competition, acquisitions, mergers and other strategic market developments and decisions to improve operational effectiveness.
January 2025: Siemens Healthineers announced the first U.S. installation of its Mammomat B.brilliant mammography system. GRACE Breast Imaging & Medical Spa of Iowa, with locations in Urbandale and Clive, became the first healthcare facility in the United States to install the new Mammomat B.brilliant. The system featured advanced 3D image acquisition and reconstruction technology, along with capabilities for full-field digital mammography (2D breast imaging), breast biopsy, and titanium contrast-enhanced mammography.
September 2024: The FDA granted expanded approval for Siemens Healthineers' mammography platform for digital breast tomosynthesis. The approval included the integration of UltraHD technology for image reconstruction, which enhanced calcification visualization, reduced metal artifacts, and enabled the generation of synthetic 2D images without subjecting patients to additional radiation.
September 2023: Hologic and Bayer announced a global collaboration to offer an integrated solution for contrast-enhanced mammography (CEM). This partnership combines Hologic’s advanced mammography systems and imaging technologies with Bayer’s contrast media and injector systems. The goal is to provide radiologists with a streamlined, high-performance CEM solution that improves the detection of breast cancer, especially in women with dense breast tissue. This collaboration enhances diagnostic accuracy by allowing better visualization of lesions and vascularization, bridging the gap between traditional mammography and MRI. It also supports workflow efficiency and standardization across breast imaging facilities globally.
August 2020: Canon Medical Systems USA, Inc. partnered with Zebra Medical Vision to integrate its AI1 automated imaging analysis solutions into clinical workflows across the U.S., aiming to support faster and more accurate diagnoses for improved patient care. Zebra Medical’s AI1 platform, powered by FDA-cleared, cloud-based AI algorithms trained on hundreds of millions of patient scans, was designed to triage acute conditions, identify incidental findings, and stratify patient risk. This collaboration marked Zebra Medical’s entry into the modality space, bringing advanced AI capabilities closer to the point of care and enhancing diagnostic efficiency within imaging systems.
| Report Attribute/Metric | Details |
| Market Size 2024 | USD 3.88 Billion |
| Market Size 2025 | USD 4.37 Billion |
| Market Size 2035 | USD 13.18 Billion |
| Compound Annual Growth Rate (CAGR) | 11.68% (2025-2035) |
| Base Year | 2024 |
| Forecast Period | 2025-2035 |
| Historical Data | 2019-2023 |
| Forecast Units | Value (USD Billion) |
| Report Coverage | Revenue Forecast, Competitive Landscape, Growth Factors, and Trends |
| Segments Covered | By Product, By Configuration, By Application, By End-User |
| Geographies Covered | North America, Europe, Asia Pacific, South America, Middle East & Africa |
| Countries Covered | The US, Canada, Germany, France, UK, Italy, Spain, Russia, China, India, Japan, South Korea, Malaysia, Thailand, Indonesia, Brazil, Mexico, Argentina, GCC Countries, South Africa |
| Key Companies Profiled | Hologic, Inc., GE HealthCare, FUJIFILM Holdings Corporation, Trivitron Healthcare Private Limited, Planmed Oy, Siemens Healthineers, PerkinElmer, Canon Medical Systems Corporation, Analogic Corporation, Shimadzu Corporation, NP JSC AMICO, VMI Médica, BEMEMS Co., Ltd., Sino Medical-Device Technology Co., Ltd., Shenzhen Landwind Industry Co., Payamed Electronic Industries Co., Medical Technologies Ltd. (MTL), Metaltronica S.p.A., Lotus Healthcare, Koninklijke Philips N.V., Allengers Medical Systems Ltd., IMS Giotto S.p.A., Shenzhen Angell Technology Co., Ltd., Konica Minolta, Inc., Electron Co. |
| Key Market Opportunities | · Expansion into emerging markets · Government initiatives and awareness programs |
| Key Market Dynamics | · Increasing prevalence of breast cancer · Technological advancements · Shift toward early and preventive diagnosis |
Frequently Asked Questions (FAQ) :
USD 3.88 Billion is the Digital Breast Tomosynthesis (DBT) Market in 2024
The 2D/3D Combo segment by Product holds the largest market share and grows at a CAGR of 11.08 % during the forecast period.
North America holds the largest market share in the Digital Breast Tomosynthesis (DBT) Market.
Hologic, Inc., GE HealthCare, FUJIFILM Holdings Corporation, Trivitron Healthcare Private Limited, Planmed Oy, Siemens Healthineers, PerkinElmer, Canon Medical Systems Corporation, Analogic Corporation, Shimadzu Corporation, NP JSC AMICO, VMI Médica, BEMEMS Co., Ltd., Sino Medical-Device Technology Co., Ltd., Shenzhen Landwind Industry Co., Payamed Electronic Industries Co., Medical Technologies Ltd. (MTL), Metaltronica S.p.A., Lotus Healthcare, Koninklijke Philips N.V., Allengers Medical Systems Ltd., IMS Giotto S.p.A., Shenzhen Angell Technology Co., Ltd., Konica Minolta, Inc., Electron Co. are prominent players in the Digital Breast Tomosynthesis (DBT) Market.
The Others segment dominated the market in 2024.
Leading companies partner with us for data-driven Insights.
Kindly complete the form below to receive a free sample of this Report
Assistant Manager He holds an experience of about 7+ years in market research and business consulting, working under the spectrum of life sciences and healthcare domains. rahul conceptualizes and implements a scalable business strategy and provides strategic leadership to the clients. his expertise lies in market estimation, competitive intelligence, pipeline analysis, customer assessment, etc. in addition to the above, his other responsibility includes strategic tracking of high growth markets & advising clients on the potential areas of focus they could direct their business initiatives
© 2025 Market Research Future ® (Part of WantStats Reasearch And Media Pvt. Ltd.)
